贝伐珠单抗靶向疗法联合常规化疗治疗晚期结直肠癌患者的效果

Effect of Targeted Therapy with Bevacizumab Combined with Conventional Chemotherapy in the Treatment of Patients with Advanced Colorectal Cancer

目的:探究晚期结直肠癌患者应用贝伐珠单抗靶向疗法与常规化疗的效果。方法:选取2020年8月—2021年8月于临沂市中医医院接受诊治的84例晚期结直肠癌患者作为研究对象,按随机数表法降患者分为对照组(n=42)与观察组(n=42)。对照组采取常规化疗,观察组在对照组基础上加用贝伐珠单抗靶向疗法。比较两组临床疗效、血清基质金属蛋白酶9(MMP-9)、血管内皮生长因子(VEGF)、肿瘤标志物[糖类抗原19-9(CA19-9)、肿瘤相关黏液抗原(CA242)]、生存期限及不良反应。结果:观察组治疗总有效率为64.29%,高于对照组的42.86%,差异有统计学意义(P<0.05);治疗后,两组MMP-9、VEGF、CA19-9及CA242水平较治疗前降低,且观察组较对照组低,观察组肿瘤无进展生存期(PFS)及总生存期(OS)较对照组长,2年生存率为83.33%,较对照组的57.14%高,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:晚期结直肠癌患者使用贝伐珠单抗靶向疗法与常规化疗的治疗方案,效果显著,可有助于增强机体免疫力,抑制肿瘤生长,使肿瘤标志物恢复正常,延长生存期限,且较安全。

Objective:To explore the effect of targeted therapy with Bevacizumab and conventional chemotherapy in the treatment of patients with advanced colorectal cancer.Method:A total of 84 patients with advanced colorectal cancer who admitted to Linyi Traditional Chinese Medicine Hospital from August 2020 to August 2021 were selected as the study objects,the patients were divided into control group(n=42)and observation group(n=42)according to the random number table method.The control group was given routine chemotherapy,while the observation group was given targeted therapy with Bevacizumab on the basis of the control group.The clinical efficacy,serum matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor(VEGF),tumor markers[carbohydrate antigen 19-9(CA19-9),tumor associated mucus antigen(CA242)],survival time and adverse reactions were compared between two groups.Result:The total effective rate of treatment in the observation group was 64.29%,which was higher than 42.86% in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum MMP-9,VEGF,CA19-9 and CA242 in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the progression-free survival(PFS)and overall survival(OS)of the observation group were longer than those of the control group,the 2-year survival rate was 83.33%,which was higher than 57.14%of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The use of targeted therapy with Bevacizumab combined with conventional chemotherapy in patients with advanced colorectal cancer has a significant effect,which can help to enhance the body's immunity,inhibit tumor growth,restore tumor markers to normal,prolong survival,and is safe.